What Is Bronchogenic Carcinoma?

Male doctor examining patient in hospital gown
Science Photo Library / Getty Images
Table of Contents
View All
Table of Contents

Bronchogenic carcinoma is the most common cancer worldwide and is the leading cancer-related cause of death in both men and women in the U.S. Bronchogenic carcinoma is another term for lung cancer. At one time it was used to describe a specific type of cancer that arises in the bronchi (the large airways of the lungs) and bronchioles (the small branches into which the airways divide). Sometimes it's still used in reference to that subtype of lung cancer, but more commonly, it's used interchangeably with lung cancer of all types.

While the survival rate for lung cancer continues to be relatively low compared to other cancers, treatment options are improving. Those diagnosed with bronchogenic carcinoma today live longer, more active lives than those diagnosed in previous generations.

If you or a loved one has been diagnosed with bronchogenic carcinoma, take time to understand how different types of lung cancers manifest and the treatment options that are available. This can help you make the best choices to battle the disease and manage your symptoms.

Types of Bronchogenic Carcinoma

There are three types of bronchogenic carcinoma:

Historically, squamous cell NSCLC was the most common type of bronchogenic carcinoma. Over the past generation, that trend has been changing as rates of squamous cell carcinoma, which is associated with smoking, have fallen as smoking habits have changed.

Adenocarcinoma is now the most common form of bronchogenic carcinoma. Approximately 40% of NSCLC patients are diagnosed with adenocarcinoma, which usually begins with tumors in the outer areas of the lungs and often isn't detected until the cancer has grown large enough to affect breathing in the central region of the lung.

Doctors use genetic testing, population data, and personalized medicine to better understand how your particular lung cancer can best be treated.

Symptoms of Bronchogenic Carcinoma

People with adenocarcinoma will often have no symptoms in the early stages of the disease. With other types of bronchogenic carcinoma, however, there may be some general signs of cancer such as:

As tumors begin to interfere with the function of the lungs and cause problems in the large airways, symptoms specifically related to breathing usually occur. Other body systems may also be affected by tumor growth or tumor secretion of substances that interfere with normal functions.

Among the most common symptoms of bronchogenic carcinoma are:


The leading risk factor for bronchogenic carcinoma is smoking, which is linked to 80 to 90% of lung cancer deaths each year.

Other leading risk factors for developing bronchogenic carcinoma include:

  • Secondhand smoke: An estimated 7,330 lung cancer deaths each year are related to secondhand smoke, which is defined as smoke exhaled by smokers and emitted from the lit end of a cigarette, pipe, or cigar, or from tobacco burning in a hookah.
  • Radon exposure: Radon is the second most common cause of NSCLC and the most common cause among never-smokers. It is responsible for roughly 21,000 lung cancer deaths each year.
  • Occupational exposure to carcinogens: Jobs in which you have direct contact with certain metals, chemicals, or fibers that cause lung cancer are very dangerous to your health. Among the substances known to raise your risk of bronchogenic carcinoma are arsenic, beryllium, vinyl chloride, polycyclic aromatic hydrocarbons (PAHs), silica, wood dust, and asbestos. Asbestos is also highly associated with mesothelioma, a rare type of cancer that affects the lungs.
  • Ionizing radiation: This type of radiation administered to the chest, usually as a treatment for another disease such as breast cancer, can significantly increase your risk of bronchogenic carcinoma.


The diagnosis of bronchogenic carcinoma may be made in several ways including imaging, tissue sample evaluations, and blood tests.


Sometimes a physician finds an abnormality on a chest X-ray prompting further evaluation with chest computed tomography (CT) or other imaging methods.

A positron emission tomography (PET) scan may also be ordered. This is the most sensitive test and may offer the best means of accurately staging the disease.

  • SCLC is usually divided into two stages: limited and extensive.
  • NSCLC is divided into four stages with subtypes and designations for each.

Your doctors will determine the stage of your cancer to assist with making your treatment plan.


A lung biopsy is also usually required to make an accurate determination about the stage of bronchogenic carcinoma.

It is also used for genetic testing, in which doctors identify genetic mutations that might be present in your lung cancer cells. If they identify certain known mutations, targeted therapies can be used to prevent the cancer cells from growing or causing further problems.

A biopsy may be done in a few different ways.

  • Bronchoscopy: A flexible tube equipped with a camera is inserted into the mouth and advanced to the location of the tumor for removal of a small tissue sample.
  • Fine needle aspiration (FNA): A special long needle is inserted into the chest to remove a small number of tumor cells.
  • Thoracoscopic biopsy: A minimally invasive procedure in which a tissue sample is taken through small incisions.
  • Open lung biopsy: The chest is opened and a tissue sample removed surgically.
  • Thoracentesis: Chest fluid samples are taken using a special needle.

When an abnormality is found on an imaging study, physicians often recommend a lung biopsy to confirm the diagnosis and learn about the genetic profile of the lung cancer.

Blood Tests

Doctors will also order a complete blood count and blood chemistries to get a comprehensive picture of your cancer and overall health. If tumors are associated with paraneoplastic syndromes, your tests may include measures of sodium and calcium levels in the blood.

Increasingly, doctors are using liquid biopsy tests to help diagnose and direct treatment of cancer. Also referred to as rapid plasma genotyping, a liquid biopsy can tell your doctor if there are cancer cells circulating in the blood. It can be used to detect genetic mutations in those cells as well. Using those results, doctors determine if your cancer might respond to treatment with targeted medications.


Low-dose CT screening for bronchogenic carcinoma is advised for people who are between 50 and 80 years old, have a 20 pack-year history of smoking, currently smoke or have quit within the last 15 years, and are healthy enough overall to tolerate treatment if diagnosed with lung cancer. Screening may decrease the mortality rate from lung cancer by at least 20%.

If you meet these criteria or have other risk factors for lung cancer, talk to your doctor about screening. Only a minority of people who are eligible get screened. As a result, lung cancers that could have been caught and more effectively treated early on aren't diagnosed until they advance to later, incurable stages.


The treatments your doctor recommends will depend on several factors, including the type and stage of lung cancer you are diagnosed with. It is important to learn about your diagnosis because being actively involved in your lung cancer care may help you have a better outcome.

Possible treatments may include:

  • Surgery: Surgery may be an option for early-stage NSCLC. However, some tumors can't be removed via surgery either due to their location or the extent of the metastasis.
  • Chemotherapy: Chemotherapy drugs kill cancer cells and may be used alone or after surgery to ensure all the cancer cells are destroyed.
  • Radiation therapy: Radiation therapy may be used to target local tumors or to support chemotherapy or surgery.
  • Targeted therapies: Targeted therapy drugs can stop cancer cells with specific genetic mutations from growing.
  • Immunotherapy: These drugs help your own immune system recognize and attack cancer cells.

New cancer treatments are continually being tested. You can enroll in clinical trials if you want to try out experimental treatments, which may offer new hope.

The Future of Treatment

Researchers are taking the new information about bronchogenic carcinoma and using it to transform the way patients are treated. A more personalized approach to lung cancer care is now the goal of oncologists, using genetic testing and personal information to tailor treatments.

New options are resulting in a durable response among some patients.


The overall five-year survival rate for bronchogenic carcinoma is about 18.6%. Prognosis varies based on the type and stage of lung cancer, with survival rates being much better when the disease is diagnosed in the earlier stages.

Though these statistics are sobering, advances in the treatment of lung cancer are improving survival—even for people with metastatic (stage 4) disease.

The survival rate for lung cancer has increased steadily over the past 40 years from 12.4% in the mid-1970s to 20.5% by 2016. This includes steady improvements in the treatment of stage 4 lung cancer.

Finding the right treatment may take some additional testing and a new perspective. Getting a second opinion, preferably at a National Cancer Institute-designated cancer center, can be valuable for you.

A Word From Verywell

While the overall incidence of bronchogenic carcinoma has been decreasing in recent years, it has increased significantly for young women who have never smoked. This shows that there is still much to learn about the risks of lung cancer and the ways doctors should approach the disease.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. American Lung Association. Lung Cancer Fact Sheet. Updated May 27, 2020.

  2. American Cancer Society. What is lung cancer? Updated October 1, 2019.

  3. Harvard Health Publishing Harvard Medical School. Squamous Cell Carcinoma of the Lung What Is It?. Updated February 2017.

  4. Li C, Lu H. Adenosquamous carcinoma of the lungOnco Targets Ther. 2018;11:4829-4835. doi:10.2147%2FOTT.S164574

  5. Jiang W, Cai G, Hu PC, Wang Y. Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Acta Pharm Sin B. 2018;8(4):530-538. doi:10.1016%2Fj.apsb.2018.04.005

  6. Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort studyBr J Cancer. 2015;112 Suppl 1(Suppl 1):S6–S13. Published 2015 Mar 31. doi:10.1038/bjc.2015.30

  7. American Cancer Society. Lung Cancer Signs and Symptoms. Updated October 1, 2019.

  8. Center for Disease Control and Prevention. What are the risk factors for lung cancer?. Updated September 18, 2019.

  9. American Lung Association. Health Effects of Secondhand Smoke. Updated: May 28, 2020

  10. Vogeltanz-holm N, Schwartz GG. Radon and lung cancer: What does the public really know?. J Environ Radioact. 2018;192:26-31. doi:10.1016/j.jenvrad.2018.05.017

  11. Gilbert ES. Ionising radiation and cancer risks: what have we learned from epidemiology?Int J Radiat Biol. 2009;85(6):467–482. doi:10.1080/09553000902883836

  12. Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancerWorld J Clin Oncol. 2014;5(3):197-223. doi:10.5306/wjco.v5.i3.197

  13. Revelo AE, Martin A, Velasquez R, et al. Liquid biopsy for lung cancers: an update on recent developmentsAnn Transl Med. 2019;7(15):349. doi:10.21037%2Fatm.2019.03.28

  14. US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation StatementJAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117

  15. Center for Disease Control. How Is Lung Cancer Diagnosed and Treated?. Updated September 18, 2019.

  16. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of lifeMethods Mol Biol. 2009;471:469–486. doi:10.1007/978-1-59745-416-2_24

  17. Pinto JA, Vallejos CS, Raez LE, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open. 2018;3(3):e000344. doi:10.1136/esmoopen-2018-000344

Additional Reading